Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease

NCT03474081 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03474081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
March 29, 2018
Completion date
July 17, 2019
Enrollment
800 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive